Measurement of Plasma, Serum, and Platelet Serotonin in Individuals With High Bone Mass and Mutations in LRP5

Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture

(2012) Karol Estrada et al.   NATURE GENETICS

The Measurement of Platelet-Poor Plasma Serotonin:A Systematic Review of Prior Reports and Recommendations for Improved Analysis

(2011) T. Brand et al.   CLINICAL CHEMISTRY

The Tryptophan Hydroxylase Inhibitor LX1031 Shows Clinical Benefit in Patients With Nonconstipating Irritable Bowel Syndrome

(2011) Philip M. Brown et al.   GASTROENTEROLOGY

Efficacy of serotonin inhibition in mouse models of bone loss

(2011) Hiroyuki Inose et al.   JOURNAL OF BONE AND MINERAL RESEARCH

LRP5, serotonin, and bone: Complexity, contradictions, and conundrums

(2011) David Goltzman   JOURNAL OF BONE AND MINERAL RESEARCH

Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5

(2011) Morten Frost et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Lrp5 functions in bone to regulate bone mass

(2011) Yajun Cui et al.   NATURE MEDICINE

Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin

(2010) Morten Frost et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Relation of serum serotonin levels to bone density and structural parameters in women

(2009) Ulrike I Mödder et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum

(2008) Vijay K. Yadav et al.   CELL